Quality of Life of Patients with Wiskott Aldrich Syndrome and X-Linked Thrombocytopenia: a Study of the Primary Immune Deficiency Consortium (PIDTC), Immune Deficiency Foundation, and the Wiskott-Aldrich Foundation.
Adolescent
Bone Marrow Transplantation
Caregivers
/ psychology
Child
Child, Preschool
Decision Making
Genetic Diseases, X-Linked
/ complications
Humans
Male
Parents
/ psychology
Patient Reported Outcome Measures
Quality of Life
Surveys and Questionnaires
/ statistics & numerical data
Survivors
/ psychology
Thrombocytopenia
/ complications
Wiskott-Aldrich Syndrome
/ complications
Young Adult
Wiskott Aldrich Syndrome (WAS)
X-linked thrombocytopenia (XLT)
bone marrow transplant (BMT)
quality of life (QOL)
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
25
03
2019
accepted:
10
09
2019
pubmed:
18
10
2019
medline:
22
7
2020
entrez:
18
10
2019
Statut:
ppublish
Résumé
We undertook a study to determine the impact of Wiskott Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) and their therapies upon the health-related quality of life (HRQOL) of patients and their families. We undertook a survey of patients and their families, who self-identified as having either WAS or XLT. We assessed the PedsQL™ 4.0, the parent proxy form, and the family impact module. These results were compared with normative data from previously published reports. Sixty-eight patients (29 patients completed both the PedsQL™ 4.0 and the parent proxy form; 21 completed only the PedsQL™ 4.0; and 18 completed only the parent proxy form) were included. In contrast to patient-reported outcomes, parents of patients who had a bone marrow transplant (BMT) reported that their children had better QOL scores compared with those who did not (82.6 vs. 73.3, p = 0.023). The QOL of patients vs. previously published normative data showed decreases in patient scores for psychosocial health (72.62 vs. 86.58, p = < 0.001), emotional functioning (69.91 vs. 82.64, p = < 0.001), social functioning (77.55 vs. 91.56, p = < 0.001), and school functioning (70.46 vs. 85.67, p = < 0.001). The family impact study revealed deficits in emotional, social, and cognitive functioning, communication, and worry. These results show that patients with WAS/XLT are significantly impacted with respect to QOL. BMT offered a better QOL for patients according to parents, but not as reported by the patients. Future studies should incorporate QOL to provide more data and a better understanding of outcomes for long-term survivors and decision-making regarding BMT.
Sections du résumé
BACKGROUND
We undertook a study to determine the impact of Wiskott Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) and their therapies upon the health-related quality of life (HRQOL) of patients and their families.
MATERIALS AND METHODS
We undertook a survey of patients and their families, who self-identified as having either WAS or XLT. We assessed the PedsQL™ 4.0, the parent proxy form, and the family impact module. These results were compared with normative data from previously published reports.
RESULTS
Sixty-eight patients (29 patients completed both the PedsQL™ 4.0 and the parent proxy form; 21 completed only the PedsQL™ 4.0; and 18 completed only the parent proxy form) were included. In contrast to patient-reported outcomes, parents of patients who had a bone marrow transplant (BMT) reported that their children had better QOL scores compared with those who did not (82.6 vs. 73.3, p = 0.023). The QOL of patients vs. previously published normative data showed decreases in patient scores for psychosocial health (72.62 vs. 86.58, p = < 0.001), emotional functioning (69.91 vs. 82.64, p = < 0.001), social functioning (77.55 vs. 91.56, p = < 0.001), and school functioning (70.46 vs. 85.67, p = < 0.001). The family impact study revealed deficits in emotional, social, and cognitive functioning, communication, and worry.
CONCLUSION
These results show that patients with WAS/XLT are significantly impacted with respect to QOL. BMT offered a better QOL for patients according to parents, but not as reported by the patients. Future studies should incorporate QOL to provide more data and a better understanding of outcomes for long-term survivors and decision-making regarding BMT.
Identifiants
pubmed: 31620947
doi: 10.1007/s10875-019-00689-2
pii: 10.1007/s10875-019-00689-2
pmc: PMC7385986
mid: NIHMS1602968
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
786-794Subventions
Organisme : NIAID NIH HHS
ID : U54 AI082973
Pays : United States
Références
Curr Opin Allergy Clin Immunol. 2003 Dec;3(6):427-36
pubmed: 14612666
Health Qual Life Outcomes. 2007 Jul 16;5:43
pubmed: 17634123
Blood. 2009 Jun 18;113(25):6288-95
pubmed: 19351959
J Clin Immunol. 2013 Jan;33(1):8-13
pubmed: 23011479
Cancer. 2002 Apr 1;94(7):2090-106
pubmed: 11932914
Health Qual Life Outcomes. 2007 Jan 03;5:2
pubmed: 17201923
Health Qual Life Outcomes. 2009 Apr 16;7:32
pubmed: 19371442
Health Qual Life Outcomes. 2004 Sep 27;2:55
pubmed: 15450120
Blood. 2008 Jan 1;111(1):439-45
pubmed: 17901250
J Pediatr. 1994 Dec;125(6 Pt 1):876-85
pubmed: 7996359
Immunol Res. 2009;44(1-3):84-8
pubmed: 19082760
J Allergy Clin Immunol. 2018 Nov;142(5):1654-1656.e7
pubmed: 30055182
J Allergy Clin Immunol. 2017 Apr;139(4):1282-1292
pubmed: 27697500
Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
Qual Life Res. 2008 Aug;17(6):895-913
pubmed: 18521721
Qual Life Res. 1996 Jun;5(3):321-9
pubmed: 8763800
Dev Neurorehabil. 2007 Jan-Mar;10(1):27-33
pubmed: 17608324
Med Care. 1999 Feb;37(2):126-39
pubmed: 10024117
Bone Marrow Transplant. 2012 Nov;47(11):1428-35
pubmed: 22426750
Blood. 2011 Aug 11;118(6):1675-84
pubmed: 21659547
Blood. 2001 Mar 15;97(6):1598-603
pubmed: 11238097
J Pediatr. 2018 Mar;194:211-217.e5
pubmed: 29198545